Please login to the form below

Not currently logged in
Email:
Password:

Arena Pharmaceuticals

This page shows the latest Arena Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Eisai takes control of weight loss drug Belviq from Arena

Eisai takes control of weight loss drug Belviq from Arena

Frustrated with lacklustre sales growth, Eisai has bought global rights to weight-loss drug Belviq from its originator Arena Pharmaceuticals. ... Meanwhile, Arena says handing over rights means it can avoid around $80m in clinical development expenses.

Latest news

More from news
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    With a similar headline value to Synageva/Alexion and building on its acquisition plans was the purchase of Par Pharmaceuticals by Endo. ... 110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Anthony Zook resigns as Vivus CEO Anthony Zook resigns as Vivus CEO

    This coup was led by investment group First Manhattan Co, which had attempted to replace the entire board of Vivus after Qsymia fell behind rival obesity drug Belviq (lorcaserin) from Arena ... Pharmaceuticals. Vivus also failed in a bid to win approval

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics